Healthcare / Medical DevicesThailand
$3.52
-0.08 (-2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-30.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
35.2x
↑EV/EBITDA
9.3x
↓ROE
5.1%
↑Gross Margin
28.9%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.4%
FCF CAGR
—
FCF margin
-1.6%
FCF / Net income
-0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.87B · net income $101.6M · FCF $-30.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.87B | $1.87B | $1.11B | $1.10B | $1.10B |
| Net Income | $101.6M | $101.6M | $180.9M | $200.7M | $175.7M |
| EBITDA | $244.2M | $244.2M | $282.4M | $295.6M | $256.2M |
| EPS | 0.15 | 0.15 | 0.26 | 0.33 | 0.25 |
| Gross Margin | 28.9% | 28.9% | 42.0% | 43.6% | 36.7% |
| Operating Margin | 8.3% | 8.3% | 19.1% | 22.7% | 20.3% |
| Net Margin | 5.4% | 5.4% | 16.2% | 18.2% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.17 | 0.12 | 0.22 |
| Current Ratio | 3.49 | 3.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-30.8M | $-30.8M | $-56.0M | $209.6M | $-179.4M |
| Returns | |||||
| ROE | 5.1% | 5.1% | 8.7% | 10.2% | 14.5% |
| Valuation | |||||
| P/E | 35.20 | 35.20 | 17.80 | 20.36 | — |
| EV/EBITDA | 9.26 | 9.26 | 9.38 | 11.24 | — |
| P/B | 1.23 | 1.23 | 1.55 | 2.08 | — |
| Growth & Yield | |||||
| Revenue Growth | 67.8% | 67.8% | 1.2% | 0.1% | — |
| EPS Growth | -43.8% | -43.8% | -20.9% | 30.1% | — |
| Dividend Yield | 8.0% | 8.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.1%
EPS terminal req.
$0.31
Spread vs growth
-73.0%
5Y implied EPS CAGR
21.1%
EPS terminal req.
$0.38
Spread vs growth
-64.9%
10Y implied EPS CAGR
15.4%
EPS terminal req.
$0.61
Spread vs growth
-59.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.7%
Start / end P/E
17.0x → 24.3x
EPS bridge
0.26 → 0.15
Residual
-18.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.